Daniel DiNapoli concentrates his practice in patent, trade secret, and unfair competition litigation and counseling. His intellectual property practice includes litigation, arbitration, and advice regarding patents and trade secrets in biotechnology, pharmaceuticals, ANDA litigations, including ANDA litigation involving Pfizer’s blockbuster drugs Viagra® and Celebrex®, medical diagnostics, surgical devices, computers, computer software, and telecommunications. Dan was recently recognized as an “IP Star” by Managing IP Handbook 2014 and recommended byThe Legal 500 United States 2013. He has also been named by Best Lawyers in America as Lawyer of the Year for 2012 in the New York City area in the field of biotechnology, by The American Lawyer Magazine as Litigator of the Month, by TheAmerican Lawyer Litigation Daily as Litigator of the Week, and by the 2011 Who’s Who Legal for life sciences in New York. He has been ranked in Best Lawyers in America in biotechnology law since 2008.
Daniel has represented leading research-based pharmaceutical and biotechnology companies, such as Pfizer Inc and Chiron Corporation (now part of Novartis), in all aspects of complex patent litigations. His experience includes patent infringement actions concerning antibiotics, anti-hypertensive drugs, antifungal drugs, treatments for erectile dysfunction, treatments for bacterial infections, anti-clotting drugs, pharmaceutical formulations, the cloning of alpha-interferon, the cloning of rennet, monoclonal antibodies, surgical devices, and methods for producing transgenic mice. Daniel’s experience also includes litigation against generic drug manufacturers under the Hatch-Waxman Act.
Daniel also has represented clients in telecommunications and computer-related patent disputes. The technologies involved include aspects of TDM and VoIP telephone communications.